Loading…
Concord Biotech (CONCORDBIO)₹596.80−2.52%Pharmaceuticals
Concord Biotech is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 44.3 against a peer median of 43.7, and ROCE of 17.0% against a peer median of 17.1%, and latest-quarter sales growth of 25.2% against a peer median of 19.3%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharma India | 16,286 | 96.2 | 29.0 | 23.3 | 0.13 | 0.6 | 2,281 | 187 | 29.8 | −32.2 | vs CONCORDBIO |
| CORONA Remedies | 15,541 | 74.9 | 33.0 | 29.5 | 0.22 | 0.4 | 1,403 | 185 | 22.3 | 15.3 | vs CONCORDBIO |
| Jubilant Pharmova | 15,359 | 43.7 | 8.9 | 6.6 | 0.51 | 0.5 | 8,307 | 398 | 17.3 | −45.1 | vs CONCORDBIO |
| Natco Pharma | 14,403 | 12.6 | 17.1 | 16.9 | 0.08 | 0.6 | 4,089 | 1,414 | −44.7 | −57.1 | vs CONCORDBIO |
| Marksans Pharma | 13,979 | 27.0 | 19.0 | 15.2 | 0.11 | 0.3 | 2,954 | 421 | 35.7 | 174.2 | vs CONCORDBIO |
| Sudeep Pharma | 13,676 | 72.4 | 27.9 | 25.2 | 0.17 | 0.1 | 641 | 174 | 20.7 | 10.6 | vs CONCORDBIO |
| Concord Biotech | 12,533 | 44.3 | 17.0 | 12.5 | 0.00 | 0.6 | 1,052 | 258 | 25.2 | 11.0 | — |
| Akums Drugs and Pharmaceuticals | 12,024 | 41.2 | 15.0 | 8.5 | 0.05 | 0.1 | 4,347 | 255 | 14.0 | 55.5 | vs CONCORDBIO |
| Viyash Scientific | 10,379 | 41.0 | 13.0 | 7.4 | 0.17 | 0.0 | 3,432 | 225 | 19.3 | 113.3 | vs CONCORDBIO |
| Blue Jet Healthcare | 10,273 | 40.2 | 26.0 | 19.9 | 0.03 | 0.2 | 946 | 248 | −17.4 | −14.3 | vs CONCORDBIO |
| Symbiotec Pharmalab | 9,997 | 88.5 | 13.0 | 11.7 | 0.34 | 0.0 | 867 | 110 | 7.5 | −53.3 | vs CONCORDBIO |
| Peer median | 13,676 | 43.7 | 17.1 | 15.2 | 0.13 | 0.3 | 2,281 | 248 | 19.3 | 10.6 |
Listed companies closest to Concord Biotech in Pharmaceuticals include AstraZeneca Pharma India, CORONA Remedies, Jubilant Pharmova, Natco Pharma, Marksans Pharma, Sudeep Pharma, Akums Drugs and Pharmaceuticals, Viyash Scientific.
AstraZeneca Pharma India, with a market cap of ₹16,286 Cr.
Concord Biotech trades at a P/E of 44.3; the median of its peer set is 43.7. A P/E above or below the median is a description, not a judgement on value.
Concord Biotech's return on capital employed is 17.0%, below the peer median of 17.1%.